

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in NAFLD.**

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1508074> since 2015-09-03T07:15:16Z

*Published version:*

DOI:10.1002/hep.27643

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



# UNIVERSITÀ DEGLI STUDI DI TORINO

***This is an author version of the contribution published on:***

*Questa è la versione dell'autore dell'opera:*

*[Hepatology 62(2):658-9,2015,doi: 10.1002/hep.27643]*

***The definitive version is available at:***

*La versione definitiva è disponibile alla URL:*

*[<http://onlinelibrary.wiley.com/doi/10.1002/hep.27643/abstract;jsessionid=44050E061E6DE9CAE107A92DA931E0E9.f03t03>]*

# **PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants**

## **affect renal disease and function in NAFLD**

**RUNNING TITLE: PNPLA3, TM6SF2 and renal function in NAFLD**

Giovanni Musso<sup>1</sup>M.D., Maurizio Cassader<sup>2</sup> Ph.D. Roberto Gambino<sup>2</sup> Ph.D.

<sup>1</sup>*Gradenigo Hospital, Italy*

<sup>2</sup>*Department of Medical Sciences, University of Turin, Italy*

*Corresponding author:*

**Giovanni Musso**

Gradenigo Hospital

Corso Regina Margherita 8,

10132 Torino, Italy.

Phone: +39-11-3475944237

Fax: +39118151320

E-mail: [giovanni\\_musso@yahoo.it](mailto:giovanni_musso@yahoo.it)

*Word count:* 499

*Tables:* 1

**KEY WORDS:** NAFLD, NASH, CKD, albuminuria

**Financial support:** this work was funded in part by the Piedmont Region Funds

Comitato Interministeriale per la Programmazione Economica 2008.

To the Editor:

we read with interest the article by Dongiovanni et al. (1) reporting on the impact of the rs58542926 C>T variant of the *Transmembrane 6 superfamily member 2* gene (*TM6SF2*) on liver histology and cardiovascular disease (CVD) risk in NAFLD. Elucidating mechanisms connecting NAFLD to CVD would have important preventive and therapeutic implications in these patients.

Chronic kidney disease (CKD) is a frequent , underappreciated condition and an established risk factor for CVD (2). In a recent meta-analysis of observational studies, the presence and severity of NAFLD at baseline were associated with an increased incidence and stage of CKD, independently of traditional risk factors (3).

CKD might be a mediator or a marker of an increased CVD risk in NAFLD. We thus explored the impact of the two polymorphisms in *PNPLA3* and *TM6SF2* genes, both modulating liver disease severity and CVD risk in NAFLD, on renal function in a cohort of 202 non-obese non-diabetic subjects (61 with biopsy proven non-cirrhotic NAFLD)(Table 1).CKD, eGFR and microalbuminuria were defined according to current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (see legend to Table 1)(2).

We found that the presence of *PNPLA3* G allele was associated with lower eGFR and with a higher prevalence of microalbuminuria and CKD(Table 1). Conversely, the *TM6SF2* T allele was associated with higher eGFR and with a lower prevalence of albuminuria and CKD ( $p<0.05$ ). On multiple regression analysis, *PNPLA3* polymorphism remained independently associated with eGFR ( $\beta=-0.368$ ,  $p=0.029$ ) and with a higher risk of microalbuminuria (OR 3.52, 95%CI 1.19-7.81,  $p=0.028$ ) and of CKD (OR 3.87, 95%CI 1.18-7.30,  $p=0.0021$ ).

Whether CKD, a correctable risk factor, mediates the effects of these polymorphisms on CVD risk in NAFLD may have relevant screening and therapeutic implications for these patients and warrants confirmation in large follow-up studies.

### **Legend to Table 1**

\* p<0.05 vs. controls

† p<0.05 vs. controls with PNPLA3 CC genotype

Data are presented as mean  $\pm$  SEM. Differences between groups were analyzed by ANOVA for normal variables; otherwise the Mann-Whitney test was used for nonparametric variables. Normality was evaluated by Shapiro-Wilk test. Fisher or chi square test were used to compare categorical variables, as appropriate. Differences were considered statistically significant at p<0.05. Analysis of different parameters and of genetic polymorphisms was made using Spearman correlation test. Genetic polymorphisms were modeled as an additive effect, that is, quantitative predictor variables reflecting the number of risk alleles (0, 1, or 2). When a relation was found on univariate analysis, multiple linear regression and logistic regression analyses were used to estimate relationship between different variables, after log transformation of skewed data.

### **Abbreviations:**

BP: blood pressure; C: cholesterol; CKD: chronic kidney disease, defined by persistent(>3 months) albuminuria and/or eGFR<60 ml/min/1.73 m<sup>2</sup>

eGFR: estimated glomerular filtration rate, calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation;

HOMA-IR: homeostasis model assessment of insulin resistance; Met Sy: metabolic syndrome as defined according to the joint statement of American Heart Association,

International Diabetes Federation and National Heart Lung and Blood Institute; PNPLA3: patatin-like phospholipase domain-containing 3; TM6SF2: Transmembrane 6

superfamily member 2; Tg: triglycerides.

Microalbuminuria was defined by an albumin-creatinine ratio of 30-300 mG/ on fresh morning urine sample;

## REFERENCES

---

(1) Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al.

*TM6SF2* gene variant disentangles nonalcoholic steatohepatitis from cardiovascular

disease Accepted manuscript online: 24 SEP 2014 04:34AM EST | DOI:

10.1002/hep.27490

(2) Stevens PE, Levin A. Evaluation and management of chronic kidney disease:

synopsis of the kidney disease: improving global outcomes 2012 clinical practice

guideline. *Ann Int Med* 2013;158:825-30

(3) Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al.

Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A

Systematic Review and Meta-analysis. *PLoS Med.* 2014 Jul 22;11: e1001680